ArticleThe oncologist2018
Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials.
Article in The oncologist, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Efficacy and Tolerability of Pazopanib in Elderly Patients with Advanced Soft Tissue Sarcoma: A Multicentre Real-World Study from Turkey.Journal of clinical medicine · 2026Article
- Article
- Global, regional, and national burden of soft tissue and extraosseous sarcomas from 1990 to 2021.Preventive medicine reports · 2024Article
- Article
- Article
- Trabectedin may be a valuable treatment option for elderly patients with metastatic soft tissue sarcomas.Frontiers in oncology · 2024Article
- Localized Synovial Sarcoma: A Population-Based Analysis of Treatment Patterns and Survival.Journal of adolescent and young adult oncology · 2023Article
- Article
- Systemic Treatment of Soft Tissue Sarcomas in the Geriatric Population.Current treatment options in oncology · 2022Review
- Treatment Strategy for Elderly Patients with Soft Tissue Sarcoma.Current oncology reports · 2022Review
- Evaluation of the efficacy of CT-guided 3D template-assistedScientific reports · 2022Article
- Impact of sarcopenia in advanced and metastatic soft tissue sarcoma.International journal of clinical oncology · 2021Article
- The age-related impact of surviving sarcoma on health-related quality of life: data from the SURVSARC study.ESMO open · 2021Article
- Doxorubicin/Adriamycin Monotherapy or Plus Ifosfamide in First-Line Treatment for Advanced Soft Tissue Sarcoma: A Pooled Analysis of Randomized Trials.Frontiers in oncology · 2021Article
- Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin.Scientific reports · 2020Article
- The Real-Life Journey of Elderly Patients in Soft Tissue and Bone Sarcomas: A Retrospective Analysis from a Sarcoma Referral Center.Journal of clinical medicine · 2020Article
- Optimising Clinical Trial Design in Older Cancer Patients.Geriatrics (Basel, Switzerland) · 2018Article
- First line palliative chemotherapy in elderly patients with advanced soft tissue sarcoma.Clinical sarcoma research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlmost half of patients diagnosed with soft tissue sarcoma (STS) are older than 65 years; however, the outcomes of elderly patients with metastatic disease are not well described. PATIENTS AND
methodsAn elderly cohort of patients aged ≥65 years was extracted from the European Organization for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group database of patients treated with first-line chemotherapy for advanced STS within 12 EORTC clinical trials. Endpoints were overall survival (OS), progression-free survival (PFS), and response rate (RR).
resultsOf 2,810 participants in EORTC trials, there were 348 elderly patients (12.4%, median 68 years; interquartile range [IQR], 67-70; maximum 84 years) and 2,462 patients aged <65 years (median 49 years; IQR, 39-57). Most elderly patients had a performance status of 0 (
conclusionElderly patients with metastatic STS treated with first-line chemotherapy were largely underrepresented in these EORTC STS trials. Their outcomes were only slightly worse than those of younger patients. Novel trials with broader eligibility criteria are needed for elderly patients. These trials should incorporate geriatric assessments and measurements of age-adjusted health-related quality of life. IMPLICATIONS FOR PRACTICE: This analysis demonstrates that elderly patients with advanced soft tissue sarcoma are underrepresented in clinical trials of first-line chemotherapy by the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Furthermore, the elderly participants were generally of excellent performance status, which is not representative of an unselected elderly population. These data provide rationale for development of novel trials for elderly patients that are not only for "elite" patients but include comprehensive geriatric assessments for risk stratification. Because chemotherapy for advanced soft tissue sarcomas is largely given with palliative intent, incorporation of health-related quality of life measures with traditional endpoints will provide a more holistic approach to future clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.